发布求助
文献互助 智能选刊 最新文献

Im Focus Onkologie最新文献

筛选
英文 中文
Checkpointinhibition plus Chemotherapie punktet beim SCLC SCLC的检查点抑制加化疗检查点
Im Focus Onkologie Pub Date : 2018-12-01 DOI: 10.1007/s15015-018-4347-6
Judith Neumaier
{"title":"Checkpointinhibition plus Chemotherapie punktet beim SCLC","authors":"Judith Neumaier","doi":"10.1007/s15015-018-4347-6","DOIUrl":"https://doi.org/10.1007/s15015-018-4347-6","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"438 3","pages":"32"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72594345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intensive Therapie verbessert Prognose bei isoliertem infradiaphragmalem HL
Im Focus Onkologie Pub Date : 2018-12-01 DOI: 10.1007/s15015-018-4335-x
B. Kreutzkamp, S. Graß
{"title":"Intensive Therapie verbessert Prognose bei isoliertem infradiaphragmalem HL","authors":"B. Kreutzkamp, S. Graß","doi":"10.1007/s15015-018-4335-x","DOIUrl":"https://doi.org/10.1007/s15015-018-4335-x","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"47 1","pages":"15"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74427849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Entrectinib bei NTRK-Fusion-positiven Tumoren 四号
Im Focus Onkologie Pub Date : 2018-12-01 DOI: 10.1007/s15015-018-4400-5
Springer Medizin
{"title":"Entrectinib bei NTRK-Fusion-positiven Tumoren","authors":"Springer Medizin","doi":"10.1007/s15015-018-4400-5","DOIUrl":"https://doi.org/10.1007/s15015-018-4400-5","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"419 1","pages":"81 - 81"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76630324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dritter CDK4/6-Inhibitor beim Mammakarzinom zugelassen 确实是美国疾病控制中心
Im Focus Onkologie Pub Date : 2018-12-01 DOI: 10.1007/s15015-018-4385-0
K. Arnheim
{"title":"Dritter CDK4/6-Inhibitor beim Mammakarzinom zugelassen","authors":"K. Arnheim","doi":"10.1007/s15015-018-4385-0","DOIUrl":"https://doi.org/10.1007/s15015-018-4385-0","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"99 1","pages":"77 - 77"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90824476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
L-Thyroxin-Einnahme könnte Fatigue unter Chemotherapie fördern 服用l .潜伏素可以帮助化疗产生Fatigue
Im Focus Onkologie Pub Date : 2018-12-01 DOI: 10.1007/s15015-018-4369-0
S. Christoph
{"title":"L-Thyroxin-Einnahme könnte Fatigue unter Chemotherapie fördern","authors":"S. Christoph","doi":"10.1007/s15015-018-4369-0","DOIUrl":"https://doi.org/10.1007/s15015-018-4369-0","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"3 1","pages":"59"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75127045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hoher Preis für Jodtherapie 碘酒便宜啊
Im Focus Onkologie Pub Date : 2018-12-01 DOI: 10.1007/s15015-018-4357-4
Christian Behrend
{"title":"Hoher Preis für Jodtherapie","authors":"Christian Behrend","doi":"10.1007/s15015-018-4357-4","DOIUrl":"https://doi.org/10.1007/s15015-018-4357-4","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"85 1","pages":"46"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76862062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
„Therapieassoziierte Mortalität praktisch eliminiert“ “准死亡”
Im Focus Onkologie Pub Date : 2018-12-01 DOI: 10.1007/s15015-018-4339-6
Springer Medizin
{"title":"„Therapieassoziierte Mortalität praktisch eliminiert“","authors":"Springer Medizin","doi":"10.1007/s15015-018-4339-6","DOIUrl":"https://doi.org/10.1007/s15015-018-4339-6","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"13 1","pages":"21-22"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77067422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Wo investieren im Digital-Health-Markt? 数字交易市场在哪里?
Im Focus Onkologie Pub Date : 2018-12-01 DOI: 10.1007/s15015-018-4381-4
Springer Medizin
{"title":"Wo investieren im Digital-Health-Markt?","authors":"Springer Medizin","doi":"10.1007/s15015-018-4381-4","DOIUrl":"https://doi.org/10.1007/s15015-018-4381-4","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"24 1","pages":"75"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76147074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neue Optionen beim fortgeschrittenen Pankreaskarzinome 主控器的新选项
Im Focus Onkologie Pub Date : 2018-12-01 DOI: 10.1007/s15015-018-4389-9
A. Bischoff
{"title":"Neue Optionen beim fortgeschrittenen Pankreaskarzinome","authors":"A. Bischoff","doi":"10.1007/s15015-018-4389-9","DOIUrl":"https://doi.org/10.1007/s15015-018-4389-9","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"90 1","pages":"78 - 78"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74528150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PARP-Inhibitoren halten Einzug in die Primärtherapie des fortgeschrittenen Ovarialkarzinoms parp抑制剂进入高级卵巢癌的初级治疗
Im Focus Onkologie Pub Date : 2018-12-01 DOI: 10.1007/s15015-018-4356-5
F. Trillsch, N. Ditsch, S. Mahner
{"title":"PARP-Inhibitoren halten Einzug in die Primärtherapie des fortgeschrittenen Ovarialkarzinoms","authors":"F. Trillsch, N. Ditsch, S. Mahner","doi":"10.1007/s15015-018-4356-5","DOIUrl":"https://doi.org/10.1007/s15015-018-4356-5","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"58 1","pages":"44-45"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77873194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信